Browsing articles in "Psychotic Disorders"


Highlights From the 2022 NEI Synapse: Optimizing Treatment for Patients With Schizophrenia
April 22, 2022   

At the 2022 NEI Synapse, Dr. Leslie Citrome delivered multiple clinically relevant presentations that provided key practical takeaways for any clinician who is striving to optimize functioning for their patients with schizophrenia...
 Continue reading
Pimavanserin For Negative Symptoms Of Schizophrenia
December 23, 2021   

Medications for schizophrenia have traditionally focused on treating positive symptoms, however negative symptoms can have serious consequences for functioning and quality of life. In a recent phase 2, 26-week randomized double-blind, placebo-controlled study, the effects of...
 Continue reading (Members only)
2021 NEI Congress Interview with the Author of Hidden Valley Road
November 6, 2021   

This very special event at the 2021 NEI Congress featured Robert Kolker, author of the New York Times bestseller and Oprah’s Book Club pick “Hidden Valley Road”. “Hidden Valley Road” is the true story of the Galvin family, a Colorado Springs family with 12 children, 6 of whom were diagnosed with schizophrenia. ...
 Continue reading
5-HT4-Receptor Agonists May Boost Cognitive Impairments Associated With Psychiatric Disorders
October 25, 2021   

Many psychiatric disorders include symptoms of cognitive impairment, which has been challenging to treat. Mounting evidence from animal studies suggest that the 5-HT4 receptor could be a promising potential treatment target for cognitive impairment because...
 Continue reading (Members only)
Association Between Antipsychotic Use and COVID-19 Mortality Among People With Serious Mental Illness
October 11, 2021   

Patients with schizophrenia who become infected with the COVID-19 virus are at increased risk of death. The authors of this retrospective study sought to investigate whether this increased risk in mortality was mediated by antipsychotic use...
 Continue reading (Members only)
Early Life Risk Markers for Psychiatric Disorders
September 21, 2021   

The consequences of preschool-age irritability on long-term functioning have not been well-studied. A recent study examined longitudinal associations of preschool irritability with psychiatric disorders and functional impairment in adolescence in a large community sample. In this study, 453 children were assessed at age....
 Continue reading (Members only)
FDA Approves Drug for Schizophrenia to be Administered at a Six Month Interval
September 1, 2021   

The U.S. Food and Drug Administration has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate for the treatment of schizophrenia in adults....
 Continue reading
Total Cost of Schizophrenia in the US is Estimated at $281.6 Billion in 2020
July 14, 2021   

The Schizophrenia & Psychosis Action Alliance released "Societal Costs of Schizophrenia and Related Disorders," a report that identifies the direct and indirect costs of caring for the estimated 2.65 million people in the U.S. living with schizophrenia. The research revealed that schizophrenia cost the US an estimated $281.6 billion in 2020...
 Continue reading
FDA Approves a New Atypical Antipsychotic With Less Adverse Effects
June 2, 2021   

The US Food and Drug Administration announced their approval of Alkermes’ combination of olanzapine and samidorphan, for the treatment of adults with schizophrenia and/or bipolar I disorder...
 Continue reading
Long-Acting Injectable Antipsychotics Cut Suicide Death Risk in Half
June 1, 2021   

In a recent population-based cohort study of patients with schizophrenia who received oral antipsychotics (OAPs), data from the Taiwan National Health Insurance Research Database was analyzed. Within this cohort, the study examined risk of suicide in those patients who switched to long-acting injectable antipsychotics compared to those who remained on OAPs...
 Continue reading (Members only)
Top of Page